摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4-二甲基-6-乙基苯酚 | 2219-79-6

中文名称
2,4-二甲基-6-乙基苯酚
中文别名
——
英文名称
2-ethyl-4,6-dimethyl-phenol
英文别名
2,4-Dimethyl-6-ethyl-phenol;4-Oxy-1.3-dimethyl-5-aethyl-benzol;2-Aethyl-4,6-dimethyl-phenol;2-Ethyl-4,6-dimethylphenol
2,4-二甲基-6-乙基苯酚化学式
CAS
2219-79-6
化学式
C10H14O
mdl
——
分子量
150.221
InChiKey
MXHAHSBTOVFDBK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 稳定性/保质期:
    存在于烟气中。

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl 3-carbomethoxyazocrotonat 、 2,4-二甲基-6-乙基苯酚silver trifluoromethanesulfonate 作用下, 以 二氯甲烷 为溶剂, 生成 methyl 2-(4-ethoxy-3-(3-ethyl-1,5-dimethyl-4-oxocyclohexa-2,5-dien-1-yl)-4-oxobutan-2-ylidene)hydrazine-1-carboxylate
    参考文献:
    名称:
    通过平行动力学不对称转化外消旋环己二酮的对映发散环化
    摘要:
    有机合成中迫切需要将可用的外消旋底物完全转化为有价值的对映体富集产物的策略。本文报道了外消旋环己二酮的第一个平行动力学不对称转化。外消旋环己二酮首先非对映选择性地转化为一对新的外消旋瞬态二烯醇中间体,然后通过手性磷酸平行质子化,得到两组带有四元立构中心的氢吲哚产物,通常具有优异的对映选择性。
    DOI:
    10.1021/acs.orglett.4c02396
  • 作为产物:
    参考文献:
    名称:
    v.Auwers; Bundesmann; Wieners, Justus Liebigs Annalen der Chemie, 1926, vol. 447, p. 180
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • PHOTOREACTIVE COMPOUNDS
    申请人:Lincker Frederic
    公开号:US20140192305A1
    公开(公告)日:2014-07-10
    The present invention relates to photoreactive compounds that are particularly useful in materials for the alignment of liquid crystals.
    本发明涉及光反应性化合物,特别适用于液晶对准材料的制作。
  • Selected Cgrp-Antagonists, Processes for Preparing Them and Their Use as Pharmaceutical Compositions
    申请人:Mueller Stephan Georg
    公开号:US20080280887A1
    公开(公告)日:2008-11-13
    The invention relates to CGRP-antagonists of general formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 are defined in claim 1 , to the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures salts and salt hydrates thereof, in particular to 10 salts thereof, which are physiologically compatible with acids or inorganic or organic bases and to compounds of general formula (I), wherein one or several hydrogen atoms are substituted by deuterium. Drugs containing said compounds, the use thereof and a method for the production thereof are also disclosed.
    该发明涉及一般式(I)的CGRP拮抗剂,其中R1、R2、R3、R4和R5如权利要求书中所定义,以及其互变异构体、同分异构体、对映体、水合物、混合物、盐及盐水合物,特别是10种盐,这些盐在生理上与酸或无机或有机碱相容,以及一般式(I)的化合物,其中一个或多个氢原子被氘代替。还披露了含有这些化合物的药物、其用途以及生产方法。
  • ADHESIVE COMPOSITION INCLUDING AT LEAST TWO TYPES OF DYES, ADHESIVE SHEET, AND DISPLAY DEVICE INCLUDING SAME
    申请人:LMS Co., Ltd.
    公开号:US20200325363A1
    公开(公告)日:2020-10-15
    The present invention discloses a adhesive sheet effectively blocking light in the ultraviolet light region without deteriorating the transmittance with respect to the visible light region and the adhesiveness and a adhesive composition including binder resin and light absorption dye dispersed in the binder resin, and it is possible to effectively block light under the 410 nm wavelength region and to be applied to a various kinds of display devices.
    本发明揭示了一种粘合片,能够有效地阻挡紫外光区域的光线,而不会降低对可见光区域的透射率和粘附性,该粘合剂组合物包括分散在粘合树脂中的粘合剂树脂和光吸收染料,并且能够有效地阻挡410纳米波长区域的光线,并适用于各种显示设备。
  • SELECTED CGRP-ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
    申请人:MUELLER Stephan Georg
    公开号:US20090253680A1
    公开(公告)日:2009-10-08
    The present invention relates to the CGRP-antagonists of general formula I wherein R 1 , R 2 , R 3 and R 4 are defined as in claim 1 , the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
    本发明涉及一般式I的CGRP拮抗剂,其中R1、R2、R3和R4如权利要求1所定义,其互变异构体、异构体、对映异构体、立体异构体、水合物、混合物及其盐和其盐的水合物,特别是与无机或有机酸或碱的生理可接受盐,以及其中一个或多个氢原子被氘取代的一般式I化合物,包含这些化合物的制药组合物,它们的用途和制备它们的过程。
  • PROCESS FOR PRODUCING ISOCYANATES
    申请人:Shinohata Masaaki
    公开号:US20100029981A1
    公开(公告)日:2010-02-04
    An object of the present invention is to provide a process that enables isocyanates to be stably produced over a long period of time at high yield without encountering various problems as found in the prior art when producing isocyanates without using phosgene. The present invention discloses a process for producing an isocyanate, comprising the steps of: reacting a carbamic acid ester and an aromatic hydroxy compound to obtain an aryl carbamate having a group derived from the aromatic hydroxy compound; and subjecting the aryl carbamate to a decomposition reaction, wherein the aromatic hydroxy compound is an aromatic hydroxy compound which is represented by the following formula (1) and which has a substituent R 1 at least one ortho position of a hydroxyl group: (wherein ring A represents an aromatic hydrocarbon ring in a form of a single or multiple rings which may have a substitute and which have 6 to 20 carbon atoms; R 1 represents a group other than a hydrogen atom in a form of an aliphatic alkyl group having 1 to 20 carbon atoms, an aliphatic alkoxy group having 1 to 20 carbon atoms, an aryl group having 6 to 20 carbon atoms, an aryloxy group having 6 to 20 carbon atoms, an aralkyl group having 7 to 20 carbon atoms or an aralkyloxy group having 7 to 20 carbon atoms, the group containing an atom selected from a carbon atom, an oxygen atom and a nitrogen atom; and R 1 may bond with A to form a ring structure).
    本发明的目的是提供一种过程,使得在不使用光气的情况下,能够稳定地高产长时间生产异氰酸酯,而不会遇到生产异氰酸酯时在先前技术中发现的各种问题。本发明公开了一种生产异氰酸酯的方法,包括以下步骤:反应一个氨基甲酸酯和一个芳香羟基化合物以获得含有源自芳香羟基化合物的基团的芳基氨基甲酸酯;并将芳基氨基甲酸酯进行分解反应,其中芳香羟基化合物是由以下式(1)表示并且在羟基位置的至少一个邻位上具有取代基R1的芳香羟基化合物:(其中,环A表示一个具有单个或多个环,并且可能具有取代基的芳香烃环,其具有6至20个碳原子;R1表示除氢原子外的基团,以具有1至20个碳原子的脂肪基烷基团,具有1至20个碳原子的脂肪基烷氧基团,具有6至20个碳原子的芳基团,具有6至20个碳原子的芳氧基团,具有7至20个碳原子的芳基烷基团或具有7至20个碳原子的芳基烷氧基团,该基团含有从碳原子、氧原子和氮原子中选择的原子;并且R1可以与A结合形成一个环状结构)。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐